U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07311850) titled 'Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity' on Dec. 29, 2025.
Brief Summary: This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.
Study Start Date: Dec. 29, 2025
Study Type: INTERVENTIONAL
Condition:
Obesity and Overweight
Intervention:
DRUG: MET097
Once-weekly MET097 administered via subcutaneous injection
DRUG: Placebo
...